Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin

Next Previous
Trial Profile

Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccine; Dendritic cell vaccines
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 26 Feb 2021 Biomarkers information updated
  • 25 Jun 2012 Planned end date changed from 1 Apr 2021 to 1 Apr 2022 as reported by ClinicalTrials.gov.
  • 09 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top